Table 2

Plasma and urine pharmacokinetics of verinurad following once-daily oral administration of varying verinurad doses in combination with allopurinol 300 mg once daily (geometric means, 95% CIs)

Verinurad (mg)Cmax (ng/mL)AUC0–24 (ng·hour/mL)Tmax (hour)t½ (hour)*fe0–24 (%)
2.54.28 (3.33–5.49)33.9 (25.4–45.3)3.83 (0.967–9.83)9.40 (6.97–12.7)0.711 (0.462–1.09)
58.20 (7.17–9.37)68.4 (56.1–83.2)3.83 (1.97–8.02)13.4 (10.0–17.8)0.844 (0.600–1.19)
7.511.2 (9.07–13.7)92.0 (74.8–113)3.00 (1.00–9.97)12.0 (8.33–17.4)0.679 (0.500–0.920)
1015.3 (13.1–18.0)145 (125–167)3.43 (1.50–6.02)20.0 (12.2–32.8)0.868 (0.669–1.13)
1522.5 (18.6–27.2)194 (158–238)3.88 (1.00–6.02)12.4 (8.12–19.0)0.634 (0.463–0.869)
2027.6 (23.2–32.7)261 (218–313)3.97 (1.50–6.02)15.8 (11.2–22.3)0.824 (0.589–1.15)
  • Tmax values are presented as median (range).

  • *Terminal t½ values were calculated from a period of less than twofold of the calculated t½ value in more than half the subjects in the same dose group.

  • AUC0–24, area under the plasma concentration–time curve from time zero to 24 hours postdose; Cmax, maximum observed concentration; fe0–24, fraction excreted in urine as unchanged drug or metabolite; Tmax, time of maximum observed plasma concentration.